UCI Scientists Win $3.5 Million Grant for Bold Addiction Research

Irvine, Calif., July 18, 2022 -The role of gene alterations resulting from childhood  adversity in adults addicted to heroin and a search for blood tests to predict addiction vulnerability are part of sweeping research that scientists are launching at the University of California, Irvine. The nearly $3.5 million five-year project to understand the opioid crisis is a collaboration of the School of Biological Sciences and the School of Medicine, as well as the Irvine Center for Addiction Neuroscience (ICAN). The National Institute on Drug Abuse is funding the work through an initiative to encourage research innovation.

Researchers will examine how early-life adversity influences epigenetics, or experience-induced changes in gene expression, and how they affect the likelihood of adult addiction.  “We want to see how these epigenetic alterations interact with the heroin experience and if there are sex differences in these processes,” said lead principal investigator Stephen Mahler, associate professor in the Department of Neurobiology and Behavior and a fellow in the Center for the Neurobiology of Learning and Memory (CNLM).

“For example, what happens upon using opioid drugs might be different between people who had scarcity of resources or chaotic environments as children and those who didn’t,” Professor Mahler said. “This could account for why some people become addicted to these drugs, while others don’t.” He noted that earlier research shows opioid-addicted women were more likely than men to have experienced stressful circumstances as children, such as those resulting from growing up amid early-life adversity.

Examining the blood’s capacity for revealing the propensity for addiction and other mental disorders is also part of the study. This work centers on extracellular vesicles, which are cell-produced droplets containing proteins and microRNAs. Researchers will compare these vesicles in blood samples and cerebral spinal fluid of rodents to learn if those in the blood hold clues about an individual’s risk of addiction or other mental disorders. If so, it could mean blood screening can provide information about the brain that helps prevent and treat addiction and related conditions.

“Gaining a better understanding of an individual’s epigenetics and brain activity opens up powerful new possibilities,” said Professor Mahler. “As an example, if someone suffers a broken leg and it is determined they are susceptible to addiction, they can be given an alternative treatment for pain. For people already dependent on opioids, we may be able to develop precise treatments that target the genetic activity causing the addiction.”

Numerous other inquiries will also take place as part of the research project. Serving as principal investigators are Christie Fowler, associate professor, Department of Neurobiology and Behavior and fellow, CNLM; Vivek Swarup, assistant professor, Department of Neurobiology and Behavior; and Tallie Z. Baram, distinguished professor, Pediatrics, Anatomy and Neurobiology, and Neurology, Danette Shepard Professor of Neurological Sciences, and fellow, CNLM. Marcelo Wood, professor, Department of Neurobiology and Behavior and fellow, CNLM, is co-investigator.

Nearly 50,000 people nationwide died from opioid-related overdoses in 2019, according to the National Institute on Drug Abuse. It calls opioid misuse and addiction “a serious national crisis that affects public health as well as social and economic welfare.”